IRON(IRON)
IRON
Signal
Leaning Bearish1↑2↓
PRICE
Prev Close
69.70
Open
69.24
Day Range66.48 – 71.11
66.48
71.11
52W Range40.00 – 99.50
40.00
99.50
45% of range
VOLUME & SIZE
Avg Volume
544.8K
FUNDAMENTALS
P/E Ratio
-10.1x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Next earnings: Aug 6, 2026 · Before open
ANALYST COVERAGE11 analysts
BUY
▲ +57.0%upside to target
L $80.00
Med $105.00consensus
H $125.00Upcoming Events
EEarnings Report
Tomorrow
May 18
DEx-Dividend
In 89 days
Aug 14
PDividend Pay
In 106 days
Aug 31
Key MetricsTTM
Market Cap$2.55B
Revenue TTM$0.00
Net Income TTM-$241.60M
Free Cash Flow-$201.34M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-36.9%
Return on Assets-32.2%
Debt / Equity0.05
Current Ratio24.00
EPS TTM$-6.28
IRON News
About
disc medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. focused on the hepcidin pathway, the master regulator of iron metabolism, disc is advancing first-in-class therapies to transform the treatment of hematologic diseases.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Brian MacDonaldFounder & Chair of Scientific Advisory Board
John D. QuiselChief Executive Officer, President & Director
Rahul KharaChief Legal Officer & Secretary
Jonathan YuChief Opearating Officer
Joseph BeaulieuSenior Vice President of Finance
Srikanth VenkatramanSenior Vice President & Head of Chemistry
Hua YangSenior Vice President & Head of Early Development and Clinical Pharmacology
Jean FranchiChief Financial Officer
Donald William NicholsonExecutive Chairman
Rahul Rajan KaushikChief Technical Officer
Steven CafféChief Regulatory Officer
William Jacob SavageChief Medical Officer
Lisa Amaya PriceChief Human Resources Officer
Pamela StephensonChief Commercial Officer
Sonia RazzettiSenior Vice President of Quality